March 2014—Qiagen expanded its strategic partnership with Exosome Diagnostics to develop a noninvasive molecular in vitro diagnostic. The novel blood-based diagnostic detects certain mutations of an undisclosed gene associated with non-small cell lung cancer and other malignancies and has the potential to be paired with several new anticancer therapeutics. Qiagen will have worldwide exclusive rights for commercialization and intends to submit the test to the FDA following clinical validation. The two companies also plan to launch the first in a series of high-performance sample preparation kits for processing nucleic acids from biofluid exosomes during the second quarter of this year.
Qiagen, 240-686-7425